A Phase 4 interventional study of Olmesartan medoxomil and Hydroclorothiazide in Hypertension, sponsored by Daiichi Sankyo. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-18.
Sponsored by Daiichi Sankyo · Phase 4, Interventional, and Treatment
A comparison of 2 different combinations of high blood pressure medications to treat hypertension
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's enrollment of 152 is above the median of 90 across 4,995 interventional studies indexed under Hypertension.
Browse Hypertension studies →Daiichi Sankyo is the lead sponsor of 316 studies on the registry; 35 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 38 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Change in systolic blood pressure from the start of the study
Change in diastolic blood pressure from the start of the study
Percent of patients who achieve target blood pressure goals
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Daiichi Sankyo